Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study

AI. Vinik, S. Perrot, EJ. Vinik, L. Pazdera, H. Jacobs, M. Stoker, SK. Long, RJ. Snijder, M. van der Stoep, E. Ortega, N. Katz,

. 2016 ; 16 (1) : 251. [pub] 20161206

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc17013358

BACKGROUND: This 52-week study evaluated the long-term safety and tolerability of capsaicin 8% w/w (179 mg) patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy (PDPN). METHODS: Phase 3, multinational, open-label, randomised, controlled, 52-week safety study, conducted in Europe. Patients were randomised to capsaicin 8% patch repeat treatment (30 or 60 min; 1-7 treatments with ≥ 8-week intervals) to painful areas of the feet plus SOC, or SOC alone. The primary objective was the safety of capsaicin 8% patch repeat treatment (30 min and 60 min applications) plus SOC versus SOC alone over 52 weeks, assessed by changes in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) total score from baseline to end of study (EOS). Secondary safety endpoints included Utah Early Neuropathy Scale (UENS) assessments and standardised testing of sensory perception and reflex function. RESULTS: Overall, 468 patients were randomised (30 min plus SOC, n = 156; 60 min plus SOC, n = 157; SOC alone, n = 155). By EoS, mean changes in Norfolk QOL-DN total score from baseline [estimated mean difference versus SOC alone; 90% CI for difference] were: 30 min plus SOC, -27.6% [-20.9; -31.7, -10.1]; 60 min plus SOC, -32.8% [-26.1; -36.8, -15.4]; SOC alone, -6.7%. Mean changes [difference versus SOC alone] in UENS total score by EoS versus baseline were: 30 min plus SOC, -2.1 [-0.9; -1.8, 0.1]; 60 min plus SOC, -3.0 [-1.7; -2.7, -0.8]; SOC alone, -1.2. No detrimental deterioration was observed in any of the Norfolk or UENS subscales by EoS with capsaicin. Also, no worsening in sensory perception testing of sharp, warm, cold and vibration stimuli was found with capsaicin by EoS. Capsaicin treatment was well tolerated and the most frequent treatment-emergent adverse events were application site pain (30 min, 28.2%; 60 min, 29.3%), burning sensation (30 min, 9.0%; 60 min, 9.6%) and application site erythema (30 min, 7.7%; 60 min, 8.9%). CONCLUSION: In patients with PDPN, capsaicin 8% patch repeat treatment plus SOC over 52 weeks was well tolerated with no negative functional or neurological effects compared with SOC alone. TRIAL REGISTRATION: ClinicalTrials.gov registration: NCT01478607 . Date of registration November 21, 2011; retrospectively registered.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013358
003      
CZ-PrNML
005      
20170427114849.0
007      
ta
008      
170413s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12883-016-0752-7 $2 doi
035    __
$a (PubMed)27919222
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vinik, Aaron I $u Eastern Virginia Medical School, Strelitz Diabetes Center, 855 W Brambleton Avenue, Room 2018, Norfolk, VA, 23510, USA. vinikai@evms.edu.
245    10
$a Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study / $c AI. Vinik, S. Perrot, EJ. Vinik, L. Pazdera, H. Jacobs, M. Stoker, SK. Long, RJ. Snijder, M. van der Stoep, E. Ortega, N. Katz,
520    9_
$a BACKGROUND: This 52-week study evaluated the long-term safety and tolerability of capsaicin 8% w/w (179 mg) patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy (PDPN). METHODS: Phase 3, multinational, open-label, randomised, controlled, 52-week safety study, conducted in Europe. Patients were randomised to capsaicin 8% patch repeat treatment (30 or 60 min; 1-7 treatments with ≥ 8-week intervals) to painful areas of the feet plus SOC, or SOC alone. The primary objective was the safety of capsaicin 8% patch repeat treatment (30 min and 60 min applications) plus SOC versus SOC alone over 52 weeks, assessed by changes in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) total score from baseline to end of study (EOS). Secondary safety endpoints included Utah Early Neuropathy Scale (UENS) assessments and standardised testing of sensory perception and reflex function. RESULTS: Overall, 468 patients were randomised (30 min plus SOC, n = 156; 60 min plus SOC, n = 157; SOC alone, n = 155). By EoS, mean changes in Norfolk QOL-DN total score from baseline [estimated mean difference versus SOC alone; 90% CI for difference] were: 30 min plus SOC, -27.6% [-20.9; -31.7, -10.1]; 60 min plus SOC, -32.8% [-26.1; -36.8, -15.4]; SOC alone, -6.7%. Mean changes [difference versus SOC alone] in UENS total score by EoS versus baseline were: 30 min plus SOC, -2.1 [-0.9; -1.8, 0.1]; 60 min plus SOC, -3.0 [-1.7; -2.7, -0.8]; SOC alone, -1.2. No detrimental deterioration was observed in any of the Norfolk or UENS subscales by EoS with capsaicin. Also, no worsening in sensory perception testing of sharp, warm, cold and vibration stimuli was found with capsaicin by EoS. Capsaicin treatment was well tolerated and the most frequent treatment-emergent adverse events were application site pain (30 min, 28.2%; 60 min, 29.3%), burning sensation (30 min, 9.0%; 60 min, 9.6%) and application site erythema (30 min, 7.7%; 60 min, 8.9%). CONCLUSION: In patients with PDPN, capsaicin 8% patch repeat treatment plus SOC over 52 weeks was well tolerated with no negative functional or neurological effects compared with SOC alone. TRIAL REGISTRATION: ClinicalTrials.gov registration: NCT01478607 . Date of registration November 21, 2011; retrospectively registered.
650    _2
$a aplikace kožní $7 D000279
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kapsaicin $x aplikace a dávkování $x škodlivé účinky $7 D002211
650    _2
$a diabetické neuropatie $x komplikace $x farmakoterapie $7 D003929
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neuralgie $x farmakoterapie $x etiologie $7 D009437
650    12
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a látky ovlivňující senzorický systém $x aplikace a dávkování $x škodlivé účinky $7 D018689
650    12
$a standardní péče $7 D059039
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Perrot, Serge $u Hôpital Hôtel Dieu, Paris Descartes University, Paris, France.
700    1_
$a Vinik, Etta J $u Eastern Virginia Medical School, Strelitz Diabetes Center, 855 W Brambleton Avenue, Room 2018, Norfolk, VA, 23510, USA.
700    1_
$a Pazdera, Ladislav $u Vestra Clinics - Dedicated Research Clinics, Rychnov nad Kneznou, Czech Republic.
700    1_
$a Jacobs, Hélène $u Astellas Pharma Europe B. V, Leiden, The Netherlands.
700    1_
$a Stoker, Malcolm $u Astellas Pharma Europe B. V, Leiden, The Netherlands.
700    1_
$a Long, Stephen K $u Astellas Pharma Europe B. V, Leiden, The Netherlands. INC Research, Camberley, UK.
700    1_
$a Snijder, Robert J $u Astellas Pharma Europe B. V, Leiden, The Netherlands.
700    1_
$a van der Stoep, Marjolijne $u Astellas Pharma Europe B. V, Leiden, The Netherlands.
700    1_
$a Ortega, Enrique $u Hospital Rio Hortega, Valladolid, Spain.
700    1_
$a Katz, Nathaniel $u Analgesic Solutions, Natick, MA, USA. Tufts University School of Medicine, Boston, MA, USA.
773    0_
$w MED00008195 $t BMC neurology $x 1471-2377 $g Roč. 16, č. 1 (2016), s. 251
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27919222 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170427115209 $b ABA008
999    __
$a ok $b bmc $g 1199823 $s 974136
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c 1 $d 251 $e 20161206 $i 1471-2377 $m BMC neurology $n BMC Neurol $x MED00008195
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Archiving options